Sarah K. Baird

1.0k total citations
29 papers, 850 citations indexed

About

Sarah K. Baird is a scholar working on Molecular Biology, Oncology and Surgery. According to data from OpenAlex, Sarah K. Baird has authored 29 papers receiving a total of 850 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Molecular Biology, 6 papers in Oncology and 5 papers in Surgery. Recurrent topics in Sarah K. Baird's work include Peptidase Inhibition and Analysis (4 papers), Protease and Inhibitor Mechanisms (4 papers) and Virus-based gene therapy research (3 papers). Sarah K. Baird is often cited by papers focused on Peptidase Inhibition and Analysis (4 papers), Protease and Inhibitor Mechanisms (4 papers) and Virus-based gene therapy research (3 papers). Sarah K. Baird collaborates with scholars based in New Zealand, United Kingdom and Sweden. Sarah K. Baird's co-authors include Tino Kurz, Ulf T. Brunk, Xi Yuan, Wei Li, Iain A. McNeish, Steven P. Gieseg, Mark B. Hampton, Nicholas R. Lemoine, Joeri L. Aerts and Michelle Lockley and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Oncogene.

In The Last Decade

Sarah K. Baird

28 papers receiving 828 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sarah K. Baird New Zealand 15 335 250 129 129 122 29 850
Tomoyuki Tanaka Japan 18 584 1.7× 247 1.0× 89 0.7× 93 0.7× 93 0.8× 46 1.3k
Hironobu Eguchi Japan 17 539 1.6× 103 0.4× 71 0.6× 102 0.8× 65 0.5× 39 1.0k
Fenglin Zhang China 21 629 1.9× 137 0.5× 116 0.9× 330 2.6× 70 0.6× 62 1.1k
Thangirala Sudha United States 23 655 2.0× 214 0.9× 47 0.4× 177 1.4× 64 0.5× 46 1.2k
Dagmar Hahn Switzerland 20 469 1.4× 170 0.7× 108 0.8× 228 1.8× 252 2.1× 38 1.2k
Niaz Mahmood Canada 15 557 1.7× 153 0.6× 49 0.4× 252 2.0× 64 0.5× 38 1.2k
Ranjini K. Sundaram United States 20 557 1.7× 369 1.5× 64 0.5× 165 1.3× 49 0.4× 45 1.4k
Steven P. Zielske United States 20 739 2.2× 320 1.3× 89 0.7× 153 1.2× 294 2.4× 31 1.2k
Xuan Zhou China 17 595 1.8× 206 0.8× 79 0.6× 184 1.4× 46 0.4× 49 1.0k
Hernán G. Fariña Argentina 18 645 1.9× 459 1.8× 144 1.1× 341 2.6× 86 0.7× 34 1.3k

Countries citing papers authored by Sarah K. Baird

Since Specialization
Citations

This map shows the geographic impact of Sarah K. Baird's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sarah K. Baird with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sarah K. Baird more than expected).

Fields of papers citing papers by Sarah K. Baird

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sarah K. Baird. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sarah K. Baird. The network helps show where Sarah K. Baird may publish in the future.

Co-authorship network of co-authors of Sarah K. Baird

This figure shows the co-authorship network connecting the top 25 collaborators of Sarah K. Baird. A scholar is included among the top collaborators of Sarah K. Baird based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sarah K. Baird. Sarah K. Baird is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Baird, Sarah K., et al.. (2021). Treatment of breast and colon cancer cell lines with anti-helmintic benzimidazoles mebendazole or albendazole results in selective apoptotic cell death. Journal of Cancer Research and Clinical Oncology. 147(10). 2945–2953. 29 indexed citations
2.
3.
Baird, Sarah K., et al.. (2020). Tissue inhibitor of matrix metalloproteinase-3 has both anti-metastatic and anti-tumourigenic properties. Clinical & Experimental Metastasis. 37(1). 69–76. 17 indexed citations
4.
Gamble, Allan B., et al.. (2018). Honey reduces the metastatic characteristics of prostate cancer cell lines by promoting a loss of adhesion. PeerJ. 6. e5115–e5115. 14 indexed citations
5.
6.
Jia, Shidong, Sarah K. Baird, Amanda Anderson, et al.. (2016). Circulating tumor cell (CTC) detection, N-terminal androgen (AR) characterization, and PTEN loss in metastatic or advanced castration resistant prostate cancer (CRPC).. Journal of Clinical Oncology. 34(2_suppl). 195–195. 1 indexed citations
7.
Anantharaman, Archana, Terence W. Friedlander, David Lu, et al.. (2016). Programmed death-ligand 1 (PD-L1) characterization of circulating tumor cells (CTCs) in muscle invasive and metastatic bladder cancer patients. BMC Cancer. 16(1). 744–744. 90 indexed citations
8.
Baird, Sarah K.. (2015). Mesenchymal Stem Cells: How Can we Realize their Therapeutic Potential in Cancer Therapy?. Journal of Clinical & Experimental Pathology. 5(1). 4 indexed citations
9.
Baird, Sarah K., et al.. (2015). Fibroblast activation protein increases metastatic potential of fibrosarcoma line HT1080 through upregulation of integrin-mediated signaling pathways. Clinical & Experimental Metastasis. 32(5). 507–516. 24 indexed citations
10.
Baird, Sarah K., et al.. (2014). Mesenchymal stem cells inhibit breast cancer cell migration and invasion through secretion of tissue inhibitor of metalloproteinase‐1 and ‐2. Molecular Carcinogenesis. 54(10). 1214–1219. 74 indexed citations
11.
Burvenich, Ingrid J.G., et al.. (2010). Preclinical Evaluation of Monoclonal Antibody 14C5 for Targeting Pancreatic Cancer. Cancer Biotherapy and Radiopharmaceuticals. 25(2). 193–205. 10 indexed citations
12.
Baird, Sarah K., et al.. (2010). Low-dose paclitaxel synergizes with oncolytic adenoviruses via mitotic slippage and apoptosis in ovarian cancer. Oncogene. 29(45). 6051–6063. 48 indexed citations
13.
14.
Baird, Sarah K., Joeri L. Aerts, Ayad Eddaoudi, et al.. (2007). Oncolytic adenoviral mutants induce a novel mode of programmed cell death in ovarian cancer. Oncogene. 27(22). 3081–3090. 64 indexed citations
15.
Leyton, Julius, Michelle Lockley, Joeri L. Aerts, et al.. (2006). Quantifying the Activity of Adenoviral E1A CR2 Deletion Mutants Using Renilla Luciferase Bioluminescence and 3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Imaging. Cancer Research. 66(18). 9178–9185. 23 indexed citations
16.
Baird, Sarah K., et al.. (2006). Oxysterol mixtures, in atheroma-relevant proportions, display synergistic and proapoptotic effects. Free Radical Biology and Medicine. 41(6). 902–910. 73 indexed citations
17.
Baird, Sarah K., et al.. (2005). OxLDL induced cell death is inhibited by the macrophage synthesised pterin, 7,8-dihydroneopterin, in U937 cells but not THP-1 cells. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research. 1745(3). 361–369. 36 indexed citations
18.
Yuan, Xi, Wei Li, Sarah K. Baird, Maria Carlsson, & Öjar Melefors. (2004). Secretion of Ferritin by Iron-laden Macrophages and Influence of Lipoproteins. Free Radical Research. 38(10). 1133–1142. 55 indexed citations
19.
Baird, Sarah K., Mark B. Hampton, & Steven P. Gieseg. (2004). Oxidized LDL triggers phosphatidylserine exposure in human monocyte cell lines by both caspase‐dependent and ‐independent mechanisms. FEBS Letters. 578(1-2). 169–174. 18 indexed citations
20.
Baird, Sarah K.. (2003). 7,8-dihydroneopterin inhibition of oxidised low density lipoprotein-induced cellular death. University of Canterbury Research Repository (University of Canterbury).

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Tomoyuki Tanaka Breakdown of academic impact, for papers by Hironobu Eguchi Breakdown of academic impact, for papers by Fenglin Zhang Breakdown of academic impact, for papers by Thangirala Sudha Breakdown of academic impact, for papers by Dagmar Hahn Breakdown of academic impact, for papers by Niaz Mahmood Breakdown of academic impact, for papers by Ranjini K. Sundaram Breakdown of academic impact, for papers by Steven P. Zielske Breakdown of academic impact, for papers by Xuan Zhou Breakdown of academic impact, for papers by Hernán G. Fariña
Rankless by CCL
2026